financetom
Business
financetom
/
Business
/
Former boss Rhodes in talks to run CBS News if Paramount-Skydance deal closes, Puck News said
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Former boss Rhodes in talks to run CBS News if Paramount-Skydance deal closes, Puck News said
Jul 18, 2025 1:50 AM

July 18 (Reuters) - David Rhodes, Sky News executive

chairman and former CBS News head, is in talks to run CBS News

again if the Skydance acquisition of the broadcaster's owner

Paramount Global ( PARAA ) closes, digital news website Puck

reported on Friday.

Rhodes, who was president at CBS from 2011 to 2019 and

previously spent a decade with Fox News, has emerged as a likely

successor at CBS News, where he may be advised by Bari Weiss,

co-founder of online news outlet Free Press, Puck said.

The New York Times reported last week that Skydance Media

CEO David Ellison had held preliminary talks to acquire Weiss'

Free Press as well.

Tom Cibrowski is the current president and executive editor

of CBS News.

Reuters could not immediately verify the Puck report. CBS

News, Paramount, Skydance and Sky News did not respond to

requests for comment. Rhodes did not respond to a request for

comment on LinkedIn.

On Thursday, CBS canceled "The Late Show with Stephen

Colbert," the most-watched late-night program on U.S. broadcast

television and a frequent platform of satire aimed at President

Donald Trump.

CBS said the show will end its 10-year run in May 2026 and

described it as "purely a financial decision against a

challenging backdrop in late-night."

CBS-owner Paramount Global ( PARAA ) is seeking approval from

the U.S. Federal Communications Commission for an $8.4-billion

merger with Skydance Media.

Paramount earlier this month agreed to settle a lawsuit

filed by Trump over an interview with his former Democratic

challenger, Kamala Harris, that CBS's "60 Minutes" broadcast in

October.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Steady Pre-Bell Monday
Sector Update: Consumer Stocks Steady Pre-Bell Monday
Oct 2, 2024
09:03 AM EDT, 09/30/2024 (MT Newswires) -- Consumer stocks were steady pre-bell Monday with the Consumer Staples Select Sector SPDR Fund ( XLP ) and Consumer Discretionary Select Sector SPDR Fund ( XLY ) recently inactive. Yunji ( YJ ) shares were up over 15% after the company regained compliance with Nasdaq's minimum bid price requirement for continued listing. Jack...
BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment
BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment
Oct 2, 2024
08:48 AM EDT, 09/30/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday it completed enrollment for the phase 3 study of BBP-418 intended for a certain type of muscular dystrophy. The study is planned to have an interim analysis in 12 months, with the primary endpoint to be evaluated in 36 months, BridgeBio said. If the trial is...
Osisko Gold Acquires Royalties on Dalgaranga Gold Project in Australia for $50 Million
Osisko Gold Acquires Royalties on Dalgaranga Gold Project in Australia for $50 Million
Oct 2, 2024
09:03 AM EDT, 09/30/2024 (MT Newswires) -- Osisko Gold Royalties ( OR ) said on Monday that it had agreed to acquire a 1.8% gross revenue royalty on the Dalgaranga Gold project in Western Australia, operated by Spartan Resources Limited The company said it also acquired a 1.35% gross revenue royalty on nearby exploration licenses to Dalgaranga. Osisko Gold Royalties...
Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma
Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma
Oct 2, 2024
09:02 AM EDT, 09/30/2024 (MT Newswires) -- Calidi Biotherapeutics ( CLDI/WS ) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses. A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved